Paeoniflorin: a natural candidate for the treatment of metabolic diseases.

IF 3.9 2区医学 Q2 NUTRITION & DIETETICS

Nutrition & Metabolism Pub Date : 2026-04-02 DOI:10.1186/s12986-026-01091-7

Minghao Ji, Haoyang Gao, Xiaotong Ma, Wei Dai, Jiabin Wu, Weihua Xiao

引用次数: 0

Abstract

The global prevalence of metabolic diseases (MetDs) is rising annually and poses a major challenge to public health. Paeoniflorin(PF), a naturally occurring phytochemical, considerably improves insulin sensitivity, glucose and lipid metabolism, bile acid metabolism, inflammation and oxidative stress. This article comprehensively reviews recent research on the role of PF in the treatment of six common MetDs: diabetes mellitus and its complications, non-alcoholic fatty liver, non-alcoholic steatohepatitis, atherosclerosis, cholestasis, and polycystic ovary syndrome, along with its potential molecular mechanisms. In addition, we summarize the pharmacological and toxicological properties of PF and propose strategies to enhance its bioavailability, opening new avenues for its clinical application. Overall, this study demonstrates that PF exhibits therapeutic potential against various MetDs and may serve as a promising candidate for the treatment of metabolic disorders.

查看原文本刊更多论文

芍药苷：治疗代谢性疾病的天然候选药物。

全球代谢性疾病的患病率每年都在上升，对公共卫生构成了重大挑战。芍药苷（Paeoniflorin， PF）是一种天然存在的植物化学物质，可显著改善胰岛素敏感性、葡萄糖和脂质代谢、胆汁酸代谢、炎症和氧化应激。本文综述了近年来关于PF在糖尿病及其并发症、非酒精性脂肪肝、非酒精性脂肪性肝炎、动脉粥样硬化、胆汁淤积、多囊卵巢综合征等6种常见疾病治疗中的作用及其潜在分子机制的研究进展。此外，我们还对其药理和毒理学特性进行了总结，并提出了提高其生物利用度的策略，为其临床应用开辟了新的途径。总的来说，这项研究表明，PF对各种方法都具有治疗潜力，可能成为治疗代谢紊乱的有希望的候选药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition & Metabolism 医学-营养学

CiteScore

8.40

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Nutrition & Metabolism publishes studies with a clear focus on nutrition and metabolism with applications ranging from nutrition needs, exercise physiology, clinical and population studies, as well as the underlying mechanisms in these aspects. The areas of interest for Nutrition & Metabolism encompass studies in molecular nutrition in the context of obesity, diabetes, lipedemias, metabolic syndrome and exercise physiology. Manuscripts related to molecular, cellular and human metabolism, nutrient sensing and nutrient–gene interactions are also in interest, as are submissions that have employed new and innovative strategies like metabolomics/lipidomics or other omic-based biomarkers to predict nutritional status and metabolic diseases. Key areas we wish to encourage submissions from include: -how diet and specific nutrients interact with genes, proteins or metabolites to influence metabolic phenotypes and disease outcomes; -the role of epigenetic factors and the microbiome in the pathogenesis of metabolic diseases and their influence on metabolic responses to diet and food components; -how diet and other environmental factors affect epigenetics and microbiota; the extent to which genetic and nongenetic factors modify personal metabolic responses to diet and food compositions and the mechanisms involved; -how specific biologic networks and nutrient sensing mechanisms attribute to metabolic variability.